The community of bacteria and other organisms that lives in our intestinal tract — known as the gut microbiome — was a hot topic at DDW 2014. Experts in the field came together to share new research about the microbiome that can potentially give patients with digestive diseases hope for new treatments.
The data presented at DDW are intriguing because FMT is currently only approved for the treatment of C. difficile. If we’re able to demonstrate, through additional research, that FMT is effective in treating diseases beyond C. diff, patients will have more treatment options available to them to help improve their quality of life.
Colleen R. Kelly, MD, an expert in the field, documents the advances in microbiome research in a new blog post on Huffington Post. She explains that the buzz around the microbiome demonstrates that we have only begun to truly understand the microbiome and how we might be able to leverage it in the development and treatment of not just digestive diseases but also of cardiovascular disease, autoimmune and metabolic disorders.